Yann-Alexandre Vano

14PUBLICATIONS
91CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Aug 05, 2025
High Circulating IL-6/IL-8 Is Associated with Intratumoral Myeloid Contexture and Poor Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade.

Lucía Carril-Ajuria, Ronan Flippot, Marie Naigeon

|Jan 23, 2025
Stratification system with dual human endogenous retroviruses for predicting immunotherapy efficacy in metastatic clear-cell renal cell carcinoma.

Xiaofan Lu, Yann-Alexandre Vano, Xiaoping Su

|Jun 19, 2023
Mesenchymal-like Tumor Cells and Myofibroblastic Cancer-Associated Fibroblasts Are Associated with Progression and Immunotherapy Response of Clear Cell Renal Cell Carcinoma.

Guillaume Davidson, Alexandra Helleux, Yann A Vano

|Jan 14, 2023
Immune Checkpoint Therapy Combinations in Adult Advanced MiT Family Translocation Renal Cell Carcinomas.

Omar Alhalabi, Jonathan Thouvenin, Sylvie Négrier

|Dec 23, 2022
Renal Carcinoma and Angiogenesis: Therapeutic Target and Biomarkers of Response in Current Therapies.

Zoé Guillaume, Marie Auvray, Yann Vano

|Nov 14, 2022
An Enhancer Demethylator Phenotype Converged to Immune Dysfunction and Resistance to Immune Checkpoint Inhibitors in Clear-Cell Renal Cell Carcinomas.

Xiaofan Lu, Yann Vano, Alexandra Helleux

Pageof 3

Frequent Collaborators

5 joint publications

Stéphane Oudard

4 joint publications

Catherine Sautes-Fridman

3 joint publications

Laurence Albiges

3 joint publications

Reza T Elaidi